1257 related articles for article (PubMed ID: 12646338)
21. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
24. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
25. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
26. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
27. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Atheroscler Suppl; 2004 Oct; 5(3):115-23. PubMed ID: 15531284
[No Abstract] [Full Text] [Related]
28. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
[TBL] [Abstract][Full Text] [Related]
29. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Schneck DW; Knopp RH; Ballantyne CM; McPherson R; Chitra RR; Simonson SG
Am J Cardiol; 2003 Jan; 91(1):33-41. PubMed ID: 12505568
[TBL] [Abstract][Full Text] [Related]
30. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
31. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
32. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Zhu JR; Tomlinson B; Ro YM; Sim KH; Lee YT; Sriratanasathavorn C
Curr Med Res Opin; 2007 Dec; 23(12):3055-68. PubMed ID: 18196620
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
[TBL] [Abstract][Full Text] [Related]
34. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Lloret R; Ycas J; Stein M; Haffner S;
Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
[TBL] [Abstract][Full Text] [Related]
35. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Deedwania PC; Gupta M; Stein M; Ycas J; Gold A;
Am J Cardiol; 2007 Jun; 99(11):1538-43. PubMed ID: 17531577
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
37. [High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Einecke D
MMW Fortschr Med; 2006 Jun; 148(24):4-5. PubMed ID: 16850796
[No Abstract] [Full Text] [Related]
38. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
[TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Calza L; Manfredi R; Colangeli V; Pocaterra D; Pavoni M; Chiodo F
Curr HIV Res; 2008 Nov; 6(6):572-8. PubMed ID: 18991624
[TBL] [Abstract][Full Text] [Related]
40. Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Karlson BW; Nicholls SJ; Lundman P; Palmer MK; Barter PJ
Atherosclerosis; 2013 May; 228(1):265-9. PubMed ID: 23510828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
